Gerard Kortekamp
Internal Medicine · Cincinnati, OHNPI 1194785113
Payments from drug & device makers
Across 89 payments — averaging $14.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$237
- Novartis$182
- AbbVie$174
- Amgen$78
- Boehringer Ingelheim$71
- Johnson & Johnson$65
- plus $464 from 16 others
What the payments were for
- Food & beverage$1,271100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $237 |
| Novartis | 10 | $182 |
| AbbVie(2 entities) | 13 | $174 |
| Amgen | 5 | $78 |
| Boehringer Ingelheim | 5 | $71 |
| Johnson & Johnson | 5 | $65 |
| Lilly USA, LLC | 4 | $53 |
| Amarin Pharma, Inc. | 4 | $53 |
| Pfizer | 4 | $49 |
| AstraZeneca | 4 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Abbott | 2 | $37 |
| Merck | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $30 |
| Boston Scientific | 2 | $26 |
| Gilead | 1 | $19 |
| Pulmonx Corporation | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$1,271 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 20 | $24,330 |
| EliquisApixaban | 48 | $18,491 |
| FarxigaDapagliflozin Propanediol | 17 | $18,210 |
| XareltoRivaroxaban | 22 | $9,376 |
| TrintellixVortioxetine Hydrobromide | 15 | $3,925 |
| Ondansetron Hcl | 25 | $3,481 |
| TradjentaLinagliptin | 12 | $3,152 |
| Atorvastatin Calcium | 219 | $2,232 |
| Sucralfate | 24 | $1,301 |
| Galantamine Hbr | 30 | $1,218 |
| Potassium Chloride | 85 | $1,199 |
| Levothyroxine Sodium | 94 | $949 |
| Mirtazapine | 35 | $762 |
| Omeprazole | 81 | $756 |
| Metoprolol Succinate | 71 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $71 | $27,48232 claims |
| PfizerEliquis | $49 | $18,49148 claims |
| AstraZenecaFarxiga | $46 | $18,21017 claims |
| Johnson & JohnsonXarelto | $65 | $9,37622 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $30 | $3,92515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cincinnati
- Antoinette PragalosCincinnati$27.8M
- Charles EgerCincinnati$8.7M
- Douglas LoganCincinnati$4.7M
- Leela VrishabhendraCincinnati$3.4M
- Traci TurnerCincinnati$645K
- Vincent MartinCincinnati$398K
- Lisa LarkinCincinnati$276K
- Mark EckmanCincinnati$255K
- Kay JohnsonCincinnati$184K
- Steven FolkerthBeavercreek$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.